Prostate Cancer
NEWS RELEASE
Released: March 2, 2021
Defense Health Program
Department of Defense Prostate Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
The FY21 Defense Appropriations Act provides funding to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government. The FY21 PCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
The mission of the FY21 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY21 PCRP Overarching Challenges:
- Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer
Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness. Studies should consider both short- and long-term quality of life outcomes. Areas of particular interest include:
- The mental and emotional health of patients and their families/caregivers
- Impact of quality of life considerations on decision-making after diagnosis and/or treatment
- Identification of vulnerable groups of men and their families at great risk of quality of life detriments
- Translation of factors or interventions that improve quality of life outcomes and overall health and wellness
- Develop treatments that improve outcomes for men with lethal prostate cancer
Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).
- Advance Health Equity and Reduce Disparities in Prostate Cancer
Applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer.
Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.
Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients.
High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans.
Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.
- Define the biology of lethal prostate cancer to reduce death
Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).
Award Mechanism | Eligibility | Key Mechanism Elements | Funding |
---|---|---|---|
Early Investigator Research Award |
By March 31, 2022 Postdoctoral Principal Investigators (PIs):
|
|
|
Physician Research Award |
At the time of application submission, the PI must be either:
|
|
|
Translational Science Award | Independent investigators at all levels. |
|
|
Health Disparity Research Award |
Established Investigators: Independent investigators at all levels New Investigators: Investigators that meet the following criteria at the application submission deadline date:
|
|
|
Idea Development Award |
Established Investigators: Independent investigators at all levels New Investigators: Investigators that meet the following criteria at the application submission deadline date:
|
|
|
Data Science Award NEW for FY21 |
Independent investigators at all levels. |
|
|
Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award NEW for FY21 |
Phase 1: Independent investigators with a faculty-level appointment (or equivalent). Phase 2: Independent investigators with a faculty-level appointment (or equivalent) that have previously received a phase 1 PCRP Consortium Research Award. |
|
Phase 1:
|
Clinical Consortium Award Modified for FY21 |
Independent investigators with a faculty-level appointment (or equivalent). |
|
Coordinating Center:
Clinical Sites:
|
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
Last updated Thursday, May 26, 2022